Henry Schein, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Henry Schein, Inc. (Nasdaq: HSIC) provides health care products and services to office-based dental, medical, and animal health practitioners worldwide through its global distribution network. Founded in 1932 and headquartered in Melville, New York, the company distributes more than 300,000 branded and private-label products from over 300 distribution centers across 33 countries and territories; its offerings span dental consumables, equipment, and digital technologies including practice management software such as Dentrix Ascend; medical supplies, pharmaceuticals, diagnostics, and equipment for physician practices, ambulatory surgery centers, and alternate care sites; technology and value-added services encompassing electronic health records, financial services, consulting, and education; as well as global specialty products like dental implants, biomaterials, endodontic, orthodontic, and orthopedic items. Henry Schein serves over 1 million customers, including general dentists, specialists, dental laboratories, veterinary practices, and institutional health care providers, with 2024 sales reaching $12.7 billion. In recent developments, the company expanded its strategic partnership with KKR & Co. in November 2025, amending the agreement to allow KKR to increase its ownership stake up to 19.9% through open-market purchases while targeting over $200 million in operating income improvements; it broadened collaboration with vVARDIS in late 2025, securing exclusive U.S. distribution rights for the drill-free Curodont Fluor Plus product effective January 2026 across general dentistry, orthodontics, and pediatric sectors; Henry Schein also completed acquisitions of medical suppliers including Prism Medical Products in 2021, Shield Healthcare and Mini Pharmacy in 2023, and Acentus in late 2024 to bolster its homecare medical supplies market presence; additionally, it reported record third-quarter 2025 results with raised full-year guidance, including 3%-4% sales growth and mid-single-digit adjusted EBITDA expansion, alongside a $229 million share repurchase program.
This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
Why Is Henry Schein (HSIC) Up 4.6% Since Last Earnings Report?
Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock
Is This the Right Time to Keep HSIC Stock in Your Portfolio?
Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript
Compared to Estimates, Henry Schein (HSIC) Q1 Earnings: A Look at Key Metrics
HSIC Q1 Earnings & Revenues Surpass Estimates, Gross Margin Rises
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
Henry Schein reaffirms annual profit forecast, beats Q1 estimates on dental strength
Henry Schein Reports First Quarter 2026 Financial Results